Cyclica Inc. and SK Chemical substances Co., Ltd. have introduced an AI-driven drug discovery and improvement partnership to develop therapies throughout a variety of illness areas.
Beneath this collaboration, Cyclica will deploy its proprietary drug discovery platforms to determine novel drug candidates for difficult organic targets throughout therapeutic areas of mutual curiosity to each corporations. SK Chemical substances can be accountable for the preclinical and medical improvement and worldwide commercialization of those prescribed drugs.
“This partnership is an amazing alternative to create revolutionary drug therapies throughout quite a lot of therapeutic areas. Having Cyclica and SK Chemical substances be part of forces will present each corporations with a aggressive benefit, permitting for main advances in understanding illness mechanisms and the potential improvement of recent therapeutics for sufferers,” stated Naheed Kurji, co-founder, president and CEO of Cyclica.
“We imagine Cyclica’s expertise will assist SK Chemical substances to develop novel therapeutic candidates towards troublesome organic targets with little data accessible. We search to create synergy arising by combining SK Chemical substances’ organizational excellence and improvement expertise with Cyclica’s experience and know-how,” stated Yun Ho Kim, head of the pharma enterprise division at SK Chemical substances.
“We’re thrilled to collaborate with SK Chemical substances. This partnership will leverage our respective strengths in creating new therapeutics for sufferers and whereas selling human well being,” stated Vern De Biasi, chief partnership officer at Cyclica.